Cathie Wood ARK Investment Management
Cathie Wood is the founder, CEO, and CIO of ARK Investment Management, an investment firm known for its focus on “disruptive innovation”. She gained widespread attention for her bold market calls and high conviction in cutting-edge technologies such as electric vehicles, genomics, and blockchain. Under her guidance, ARK’s exchange-traded funds (ETFs) attracted substantial interest from both retail and institutional investors. Wood’s investment philosophy emphasizes research-driven analysis and long-term growth potential, positioning her as one of today’s most influential voices in the world of finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$114M |
| 2 |
XYZ
Block Inc
XYZ
|
+$78M |
| 3 |
Teladoc Health
TDOC
|
+$34.8M |
| 4 |
Zillow
Z
|
+$29.6M |
| 5 |
Teradyne
TER
|
+$29.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$107M |
| 2 |
JD.com
JD
|
+$73.4M |
| 3 |
RHT
Red Hat Inc
RHT
|
+$68.7M |
| 4 |
Pacific Biosciences
PACB
|
+$49.3M |
| 5 |
XLNX
Xilinx Inc
XLNX
|
+$44.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.47% |
| 2 | Healthcare | 29.65% |
| 3 | Communication Services | 15.82% |
| 4 | Consumer Discretionary | 9.58% |
| 5 | Industrials | 4.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Iovance Biotherapeutics
IOVA
$3.76B
| $6.43M | 0.26% |
726,360
+301,540
| +71% | +$2.91M |
|
52
Mercado Libre
MELI
$97.5B
| $6.37M | 0.26% |
21,765
-100,582
| -82% | -$32.6M |
|
53
Aptiv
APTV
$10B
| $5.75M | 0.23% |
93,442
-519,343
| -85% | -$37.6M |
|
|
LOXO
54
DELISTED
Loxo Oncology, Inc
LOXO
| $5.66M | 0.23% |
+40,440
| New | +$6.14M |
|
55
Trimble
TRMB
$14B
| $5.65M | 0.23% |
171,609
-11,808
| -6% | -$434K |
|
|
ZUO
56
DELISTED
Zuora, Inc.
ZUO
| $5.62M | 0.23% |
309,589
+10,320
| +3% | +$198K |
|
57
Atlassian
TEAM
$43.5B
| $5.36M | 0.22% |
+60,252
| New | +$4.77M |
|
58
Regeneron Pharmaceuticals
REGN
$85.9B
| $5.2M | 0.21% |
13,921
-9,319
| -40% | -$3.41M |
|
|
RUBY
59
DELISTED
Rubius Therapeutics, Inc
RUBY
| $5.07M | 0.21% |
315,152
+126,884
| +67% | +$2.31M |
|
60
Pinduoduo
PDD
$126B
| $4.93M | 0.2% |
+219,730
| New | +$4.63M |
|
61
Autodesk
ADSK
$53.6B
| $4.73M | 0.19% |
36,761
-641
| -2% | -$86.6K |
|
|
EB
62
DELISTED
Eventbrite
EB
| $4.24M | 0.17% |
+152,573
| New | +$4.52M |
|
63
Incyte
INCY
$25.9B
| $4.21M | 0.17% |
66,147
+2,504
| +4% | +$163K |
|
64
Twilio
TWLO
$34.6B
| $4.04M | 0.16% |
+45,237
| New | +$3.67M |
|
65
Align Technology
ALGN
$11.5B
| $3.96M | 0.16% |
18,914
+6,932
| +58% | +$1.75M |
|
66
Arcturus Therapeutics
ARCT
$382M
| $3.69M | 0.15% |
815,176
+41,404
| +5% | +$255K |
|
67
Codexis
CDXS
$183M
| $3.58M | 0.15% |
+214,298
| New | +$3.7M |
|
68
Alphabet (Google) Class C
GOOG
$4.18T
| $3.1M | 0.13% |
59,860
-250,020
| -81% | -$13.4M |
|
|
BLCM
69
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $3.02M | 0.12% |
103,349
+44,328
| +75% | +$1.97M |
|
|
ANSS
70
DELISTED
Ansys
ANSS
| $3.01M | 0.12% |
21,053
-444
| -2% | -$69K |
|
71
Pluri
PLUR
$18.5M
| $2.67M | 0.11% |
42,339
+6,186
| +17% | +$531K |
|
72
Cognex
CGNX
$10.2B
| $2.67M | 0.11% |
68,945
+8,649
| +14% | +$375K |
|
73
Intuitive Surgical
ISRG
$134B
| $2.36M | 0.1% |
14,778
+3,951
| +36% | +$670K |
|
74
Elbit Systems
ESLT
$34.7B
| $2.27M | 0.09% |
19,952
-340
| -2% | -$41.2K |
|
75
HP
HPQ
$27.2B
| $2M | 0.08% |
97,957
-22,120
| -18% | -$516K |
|
Similar funds
Cathie Wood's Q4 2018 Portfolio in Review
As of Q4 2018, Cathie Wood held 214 positions worth $2.46B, down 26% from $3.31B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Cathie Wood withdrew a net $137M in Q4 2018, closing 20 positions and reducing 94 holdings. Its most notable exit was Biogen, an estimated $7.95M position sold in full.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Cathie Wood opened a new position in Loxo Oncology, Inc worth $5.66M.
- Cathie Wood's largest Q4 2018 buy was Loxo Oncology, Inc: 40,440 shares worth $5.66M.
- Cathie Wood added most to NVIDIA in Q4 2018, an estimated $114M increase.
- Cathie Wood's biggest Q4 2018 reduction was Tesla, cutting an estimated $107M.
- Cathie Wood fully exited Biogen in Q4 2018, selling an estimated $7.95M.
- Cathie Wood's ten largest holdings make up 45% of its $2.46B portfolio in Q4 2018.
- Cathie Wood opened 12 new positions and closed 20 in Q4 2018.
- Cathie Wood's portfolio value fell 26% quarter-over-quarter to $2.46B.
Based on ARK Investment Management's 13F filing for Q4 2018, filed 1 Feb 2019.